We are live on ! Find out more
FVFIGP

Flagship Ventures Fund IV General Partner Portfolio holdings

AUM $585M
This Fund
S&P 500
This Quarter Est. Return
+1.42%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$585M
AUM Growth
–
Cap. Flow
+$635M
Cap. Flow %
108.56%
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MCRB icon
Seres Therapeutics
MCRB
+$372M
2
EDIT icon
Editas Medicine
EDIT
+$167M
3
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$87.2M
4
TTOO
T2 Biosystems, Inc
TTOO
+$6.68M
5
CARM
Carisma Therapeutics
CARM
+$1.86M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
1
Seres Therapeutics
MCRB
$49.6M
$368M 62.99%
+634,144
New +$372M
EDIT icon
2
Editas Medicine
EDIT
$444M
$121M 20.67%
+4,955,316
New +$167M
SYRS
3
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$87.2M 14.92%
+480,666
New +$87.2M
TTOO
4
DELISTED
T2 Biosystems, Inc
TTOO
$5.85M 1%
+148
New +$6.68M
CARM
5
DELISTED
Carisma Therapeutics
CARM
$2.46M 0.42%
+73,321
New +$1.86M

Similar funds

ZA
Zweig Advisers Hartford, Connecticut $586M AUM 1.34% 1-Year Est. Return
VFS
VSR Financial Services Overland Park, Kansas $607M AUM 0.85% 1-Year Est. Return
WA
Westport Advisers Westport, Connecticut $542M AUM 2.07% 1-Year Est. Return
TT
Tiedemann Trust Wilmington, Delaware $542M AUM 1.38% 1-Year Est. Return
ICAS
Investors Capital Advisory Services Lynnfield, Massachusetts $521M AUM 1.51% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
THSP
Taube Hodson Stonex Partners London, United Kingdom $488M AUM 4.7% 1-Year Est. Return
JWCA
J.W. Childs Associates Waltham, Massachusetts $456M AUM 0% 1-Year Est. Return

Flagship Ventures Fund IV General Partner's Q2 2016 Portfolio in Review

Q2 2016 is the first quarter with a 13F filing on record for Flagship Ventures Fund IV General Partner, which disclosed 5 positions worth $585M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Seres Therapeutics: 634,144 shares worth $368M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets.

  • Flagship Ventures Fund IV General Partner's largest Q2 2016 buy was Seres Therapeutics: 634,144 shares worth $368M.
  • Flagship Ventures Fund IV General Partner's ten largest holdings make up 100% of its $585M portfolio in Q2 2016.
  • Flagship Ventures Fund IV General Partner disclosed 5 positions in Q2 2016, its first 13F filing on record.

Based on Flagship Ventures Fund IV General Partner's 13F filing for Q2 2016, filed 15 Aug 2016.